Jan 09, 2024 / 06:30PM GMT
Jessica Fye J.P. Morgan Securities LLC-Moderator
Great. Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at J.P. Morgan, and we're continuing the conference this morning with Denali.
I'm joined on stage by the company's CEO, Ryan Watts. (Conference Instructions)
So with that, let me pass it over to Ryan.
Ryan Watts Denali Therapeutics Inc-CEO
Great. Thank you, Jess. Great to be back at JPMorgan. Great to see many of you friends and colleagues over the years and very excited to present our update for 2024 and talk a little bit about what's happened in the last year and set the stage for the company going forward.
So let me begin by saying that as we founded Denali, our primary purpose that we set out to after was to defeat degeneration and to focus on some of the broader degenerative diseases like Alzheimer's and Parkinson's. But you'll recall, eight or nine years ago, it's a very difficult time in the space, and yet so much has changed in the last two to three years, especially in the
Denali Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers